JBM HEALTHCARE (02161) announces mid-year performance. The profit attributable to equity holders of the company is approximately HK$115 million, an increase of about 20.0% year-on-year.

JBM HEALTHCARE (02161) announced its interim performance for the six months ending on September 30, 2025, with revenue of approximately HK$430 million, an increase of about 7.7% compared to the previous year. The profit attributable to equity holders of the company was approximately HK$115 million, an increase of about 20.0% compared to the previous year. Earnings per share were 14.12 HK cents, with an interim dividend of 9.75 HK cents per ordinary share. The announcement stated that the growth in performance was mainly driven by strong sales of core brands, especially Hejigong in the branded pharmaceuticals division and Baojiwan in the branded traditional Chinese medicine division, benefiting from focused brand management and effective marketing execution. The group's Chinese medicine granule business also showed stable performance, making a continuous contribution to the portfolio of branded health businesses.